Diagnosis and management of pancreatic cancer

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 4, 2009, Pages 445-454

  Collins, A ^a   Bloomston, M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma, diagnosis; CA19 9 antigen; Chemotherapy, adjuvant; MicroRNAs; Pancreatic neoplasms; Pancreaticoduodenectomy

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; MICRORNA;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHOLANGIOGRAPHY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE EXPRESSION; HUMAN; LYMPHADENECTOMY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEDLINE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS CANCER; PANCREATICODUODENECTOMY; RADIODIAGNOSIS; REVIEW;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; CHEMOTHERAPY, ADJUVANT; CHOLANGIOGRAPHY; FLUOROURACIL; HUMANS; LAPAROSCOPY; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77949272555     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Klapman J, Malafa MP. Early Detection of Pancreatic Cancer: Why, Who, and How to Screen. Cancer Control 2008;15280-7.
3. Lau WY, Lai EC. Development and Controversies of Adjuvant Therapy for Pancreatic Cancer. Hepatobiliary Pancreat Dis Int 2008;7:121-5.
4. Rosa JA, Van Linda BM, Abourizk NN. New-Onset Diabetes Mellitus as a Harbinger of Pancreatic Carcinoma. A Case Report and Literature Review. J Clin Gastroenterol 1989;11:211-5.
5. Ogawa Y, Tanaka M, Inoue K, Yamaguchi K, Chijiwa K, Mizumoto K, et al. A Prospective Pancreatographic Study of the Prevalence of Pancreatic Carcinoma in Patients with Diabetes Mellitus. Cancer 2002;94:2344-9.
6. Agarwal B, Abu-Hamda E, Molke KL, Correa AM, Ho L. Endoscopic Ultrasound-Guided Fine Needle Aspiration and Multidetector Spiral CT in the Diagnosis of Pancreatic Cancer. Am J Gastroenterol 2004;99:844-850.
7. Johnson CD. Pancreatic Carcinoma: Developing a Protocol for Multi-Detector Row CT. Radiology 2001;220:3-4.
8. Hernandez LV, Bhutani MS. Emerging Applications of Endoscopic Ultrasound in Gastrointestinal Cancers. Gastrointest Cancer Res 2008;2:198-202.
9. Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, et al. Thin-section Contrast-enhanced Computed Tomography Accurately Predicts the Resectability of Malignant Pancreatic Neoplasms. Am J Surg 1994;167:104-111.
10. Freeny PC. Radiologic Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Radiol Clin North Am 1989;27:121-8.
11. Tempera M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, et al. Pancreatic Adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Netw 2007;5:998-1033.
12. Rosch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schusdziarra V, et al. Staging of Pancreatic and Ampullary Carcinoma by Endoscopic Ultrasonography. Comparison with Conventional Sonography, Computed Tomography, and Angiography. Gastroenterology 1992;102:188-99.
13. Varadarajulu S, Wallace MB. Applications of Endoscopic Ultrasonography in Pancreatic Cancer. Cancer Control 2004;11:15-22.
14. Santo E. Pancreatic Cancer Imaging: Which Method? JOP 2004;5:253-7.
15. Lerut JP, Gianello PR, Otte JB, Kestens PJ. Pancreaticoduodenal resection. Surgical Experience and Evaluation of Risk Factors in 103 Patients. Ann Surg 1984;199: 432-7.
16. Bottger TC, Junginger T. Factors Influencing Morbidity and Mortality After Pancreaticoduodenectomy: Critical Analysis of 221 Resections. World J Surg 1999;23: 164-71.
17. Heslin MJ, Brooks AD, Hochwald SN, Harrison LE, Blumgart LH, Brennan MF. A Preoperative Biliary Stent is Associated With Increased Complications After Pancreatoduodenectomy. Arch Surg 1998;133:149-54.
18. Sohn TA, Yeo CJ, Cameron JL, Pitt HA, Lillemoe KD. Do Preoperative Biliary Stents Increase Postpancreaticoduodenectomy Complications? J Gastrointest Surg 2000; 4:258-67.
19. Lygidakis NJ, Van der Heyde MN, Lubbers MJ. Evaluation of Preoperative Biliary Drainage in the Surgical Management of Pancreatic Head Carcinoma. Acta Chir Scand 1987;153:665-8.
20. Lai EC, Mok FP, Fan ST, Lo CM, Chu KM, Liu CL et al. Preoperative Endoscopic Drainage for Malignant Obstructive Jaundice. Br J Surg 1994;81:1195-8.
21. Saleh MM, Norregaard P, Jorgensen HL, Andersen PK, Matzen P. Preoperative Endoscopic Stent Placement Before Pancreaticoduodenectomy: a Meta-analysis of the Effect on Morbidity and Mortality. Gastrointest Endosc 2002;56:529-34.
22. Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, et al. Preoperative Carbohydrate Antigen 19-9 is Most Predictive of Malignancy in Older Jaundiced Patients Undergoing Pancreatic Resection. Pancreas 2006;33:246-9.
23. Zhang S, Wang Y, Sun C, Lu Y, Wu L. Clinical Value of Serum CA19-9 Levels in Evaluating Resectability of Pancreatic Carcinoma. World J Gastroenterol 2008;14: 3750-3.
24. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Postoperative Adjuvant Chemoradiation Improves Survival. A Prospective, Single-Institution Experience. Ann Surg 1997;225: 621-33.
25. Dillhoff M, Yates R, Wall K, Muscarella P, Melvin WS, Ellison EC et al. Intraoperative Assessment of Pancreatic Neck Margin at the Time of Pancreaticoduodenectomy Increases Likelihood of Margin-Negative Resection in Patients with Pancreatic Cancer. J Gastrointest Surg 2009;13:825-30.
26. Reddy SK, Tyler DS, Pappas TN, Clary BM. Extended Resection for Pancreatic Adenocarcinoma. Oncologist 2007;12:654-63.
27. Bahra M, Neumann U. Surgical Techniques for Resectable Pancreatic Cancer. Recent Results Cancer Res 2008;177:29-38.
28. Traverso LW, Longmire WP Jr. Preservation of the Pylorus in Pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959-62.
29. Kozuschek W, Reith HB, Waleczek H, Haarmann W, Edelmann M, Sonntag D. A Comparison of Long Term Results of the Standard Whipple Procedure and the Pylorus Preserving Pancreatoduodenectomy. J Am Coll Surg 1994;178:443-53.
30. Seiler CA, Wagner M, Sadowski C, Kulli C, Buchler MW. Randomized Prospective Trial of PylorusPreserving vs. Classic Duodenopancreatectomy (Whipple Procedure): Initial Clinical Results. J Gastrointest Surg 2000;4:443-52.
31. Morel P, Mathey P, Corboud H, Huber O, Egeli RA, Rohner A. Pylorus-Preserving Duodenopancreatectomy: Long-Term Complications and Comparison with the Whipple Procedure. World J Surg 1990;14:642-6.
32. Lin PW, Lin YJ. Prospective Randomized Comparison Between Pylorus-Preserving and Standard Pancreaticoduodenectomy. Br J Surg 1999;86:603-7.
33. Roder JD, Stein HJ, Huttl W, Siewert JR. PylorusPreserving versus Standard Pancreaticoduodenectomy: an Analysis of 110 Pancreatic and Periampullary Carcinomas. Br J Surg 1992;79:152-5.
34. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD et al. Impact of Total Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: a Large, Population-Based Analysis. Ann Surg Oncol 2008;15:165-74.
35. Pedrazolli S, Beger HG, Obertop H, Ander-Sandberg A, Fernandez-Cruz L, Henne-Bruns D et al. A Surgical and Pathological Based Classification of Resective Treatment of Pancreatic Cancer. Summary of an International Workshop on Surgical Procedures in Pancreatic Cancer. Dig Surg 1999;16:337-45.
36. Glanemann M, Shi B, Liang F, Sun XG, Bahra M, Jacob D et al. Surgical Strategies for Treatment of Malignant Pancreatic Tumors: Extended, Standard, or Local Surgery? World J Surg Oncol 2008;6:123.
37. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK et al. Pancreaticoduodenectomy with Vascular Resection: Margin Status and Survival Duration. J Gastrointest Surg 2004;8935-49.
38. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR et al. Rationale for En Bloc Vein Resection in the Treatment of Pancreatic Adenocarcinoma Adherent to the Superior Mesenteric-Portal Vein Confluence. Pancreatic Tumor Study Group. Ann Surg 1996;223:154-62.
39. Launois B, Stasik C, Bardaxoglou E, Meunier B, Campion JP, Greco L et al. Who Benefits From Portal Vein Resection During Pancreaticoduodenectomy for Pancreatic Cancer? World J Surg 1999;23:926-9.
40. Taschieri AM, Elli M, Rovati M, Sampietro GM, Cristaldi M, Danelli P et al. Surgical Treatment of Pancreatic Tumors Invading the Spleno-Mesenteric-Portal Vessels. An Italian Multicenter Survey. Hepatogastroenterology. 1999 Jan-Feb; 46(25):492-7.
41. Clavien PA, Rudiger HA. A Simple Technique of Portal Vein Resection and Reconstruction During Pancreaticoduodenectomy. J Am Coll Surg 1999;189: 629-34.
42. van Geenen RC, ten Kate FJ, de Wit LT, van Gulik TM, Obertop H, Gouma DJ. Segmental Resection and Wedge Excision of the Portal or Superior Mesenteric Vein During Pancreatoduodenectomy. Surgery 2001;129:158-63.
43. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Evans DB et al. Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Ann Surg 2007;246:52-60.
44. Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K et al. Preoperative Serum CA19-9 and Dissected Peripancreatic Tissue Margin as Determiners of Long-Term Survival in Pancreatic Cancer. Ann Surg Oncol 2009;16:1231-40.
45. Kinsella TJ 08, Seo Y, Willis J, Stellate TA, Siegel CT, Harpp D et al. The Impact of Resection Margin Status and Postoperative CA19-9 Levels on Survival and Patterns of Recurrence After Postoperative High-Dose Radiotherapy with 5-FU Based Concurrent Chemotherapy for Resectable Pancreatic Cancer. Am J Clin Oncol 2008;31:446-53.
46. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE et al. A Margin-Negative R0 Resection Accomplished with Minimal Postoperative Complications is the Surgeon's Contribution to Long-Term Survival in Pancreatic Cancer. J Gastrointest Surg 2006;10:1338-45.
47. Khalifa MA, Maksymov V, Rowsell C. Retroperitoneal Margin of the Pancreaticoduodenectomy Specimen: Anatomic Mapping for the Surgical Pathologist. Virchows Arch 2009;454:125-31.
48. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ. Margin Clearance and Outcome in Resected Pancreatic Cancer. J Clin Oncol 2009;27:2855-62.
49. Gagner M, Pomp A. Laparoscopic Pylorus-Preserving Pancreatoduodenectomy. Surg Endosc 1994;8:408-10.
50. Palanivelu C, Jani K, Senthilnathan P, Parthasarathi R, Rajapandian S, Madhankumar MV. Laparoscopic Pancreaticoduodenectomy: Techniques and Outcomes. J Am Coll Surg 2007;205:222-30.
51. Fazal S, Saif MW. Supportive and Palliative Care of Pancreatic Cancer. JOP 2007;8:240-53.
52. Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO et al. Effect of a Neurolytic Celiac Plexus Block on Pain Relief, Quality of Life, and Survival in Patients with Unresectable Pancreatic Cancer: a Randomized Controlled Trial. JAMA 2004;291:1092-9.
53. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical Splanchnicectomy in Patients with Unresectable Pancreatic Cancer: a Prospective Randomized Trial. Ann Surg 1993 May; 217(5) 447-55.
54. Moss AC, Morris E, Mac Mathuna P. Palliative Biliary Stents for Obstructing Pancreatic Carcinoma. Cochrane Database Syst Rev 2006 Apr 19; (2):CD004200.
55. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al. Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation following Resection of Pancreatic Adenocarcinoma: a Randomized Controlled Trial. JAMA 2008;299:1019-26.
56. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochester H, Lenzi A et al. Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients with Pancreatic Adenocarcinoma. J Clin Oncol 2003;21:3402-8.
57. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. Adjuvant Chemotherapy with Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: a Randomized Controlled Trial. JAMA 2007;297: 267-77.
58. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P et al. Influence of Resection Margins on Survival for Patients with Pancreatic Cancer Treated by Adjuvant Chemoradiation and/ or Chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-68.
59. Koshy MC, Landry JC, Cavanaugh SX, Fuller CD, Willett CG, Abrams RA et al. A Challenge to the Therapeutic Nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005;61:965-6.
60. Crane CH, Ben-Josef E, Small W Jr. Chemotherapy for Pancreatic Cancer. N Engl J Med 2004; 350:2713-5.
61. Evans DB, Hess KR, Pisters PW. ESPAC-1 Trial of Adjuvant Therapy for Resectable Adenocarcinoma of the Pancreas. Ann Surg 2002;236:694-6.
62. Regine WF, Winter KW, Abrams RA et al. RTOG 9704 a Phase II Study of Adjuvant Pre and Post Chemoradiation (CRT) 5-FU vs. Gemcitabine(G) for Resected Pancreatic Adenocarcinoma. J Clin Oncol 2006; 24: No 18S (June 20 suppl.) Abstract 4007.
63. Burris III H, Rocha-Lima C. New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. The Oncologist 2008;13: 289-98.
64. Talar-Wojnarowska R, Malecka-Panas E. Molecular Pathogenesis of Pancreatic Adenocarcinoma: Potential Clinical Implications. Med Sci Monit 2006;12:RA186-RA193.
65. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of Anticancer Drug Sensitivity in Pancreatic Cancer. Mol Cancer Ther 2006;5:1387-95.
66. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival. J Gastrointest Surg 2008;12:2171-6.
67. Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J et al. MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis. JAMA 2007;297: 1901-8.